Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Tafinlar (dabrafenib)
i
Other names:
GSK2118436, GSK436, 2118436, DRB 436, GSK-2118436A, GSK2118436A, GSK-2118436, GSK 2118436
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(211)
News
Trials
Company:
BeiGene, Novartis
Drug class:
BRAF inhibitor
Related drugs:
‹
vemurafenib (212)
PLX4720 (65)
encorafenib (63)
VS-6766 (27)
FORE-8394 (20)
RAF265 (7)
ERAS-254 (7)
GDC 0879 (6)
ABM-1310 (5)
RXDX-105 (5)
RAF709 (3)
HI-511 (1)
SB-590885 (1)
BGB-3245 (1)
PF-07284890 (1)
ARQ 736 (0)
ASN003 (0)
BDTX-4933 (0)
BMS-908662 (0)
PF-07799933 (0)
RX208 (0)
NSC311152 (0)
vemurafenib (212)
PLX4720 (65)
encorafenib (63)
VS-6766 (27)
FORE-8394 (20)
RAF265 (7)
ERAS-254 (7)
GDC 0879 (6)
ABM-1310 (5)
RXDX-105 (5)
RAF709 (3)
HI-511 (1)
SB-590885 (1)
BGB-3245 (1)
PF-07284890 (1)
ARQ 736 (0)
ASN003 (0)
BDTX-4933 (0)
BMS-908662 (0)
PF-07799933 (0)
RX208 (0)
NSC311152 (0)
›
Associations
(211)
News
Trials
Search handles
@ArndtVogel
@BenjaminBesseMD
@DrBonillaOnc
@DrJNaidoo
@DrSanjayPopat
@DrYukselUrun
@Dr_Ivanoncologo
@GautschiOliver
@MPishvaian
@NicoleKuderer
@RielyMD
@SCTNB
@StephenVLiu
@TalhaBadarMD
@UmutDisel
@VivekSubbiah
@ahmadalhader
@ilyassahinMD
@jasonlukemd
@neerajaiims
@saadvikdr
@tnewsomdavis
@weldeiry
Search handles
@ArndtVogel
@BenjaminBesseMD
@DrBonillaOnc
@DrJNaidoo
@DrSanjayPopat
@DrYukselUrun
@Dr_Ivanoncologo
@GautschiOliver
@MPishvaian
@NicoleKuderer
@RielyMD
@SCTNB
@StephenVLiu
@TalhaBadarMD
@UmutDisel
@VivekSubbiah
@ahmadalhader
@ilyassahinMD
@jasonlukemd
@neerajaiims
@saadvikdr
@tnewsomdavis
@weldeiry
Filter by
Latest
9ms
Check out Dr. Vivek Subbiah @VivekSubbiah @SarahCannonDocs discussing #ASCO23 Expanding the Benefit - Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAFV600E+ Adult & Pediatric Solid Tumors #LCSM #GICSM #BCSM https://t.co/RJQckViT7V (@Sameh_VuMedi)
9 months ago
Clinical • Pan tumor
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
9ms
Case report of a patient with #EGFR mutant NSCLC who developed an acquired #BRAF V600E mutation on osimertinib as well as leptomeningeal disease and achieved durable control with osimertinib, dabrafenib, and trametinib. #JTOCRR @JTOonline https://t.co/TcycKvLI9x (@StephenVLiu)
9 months ago
Clinical
|
EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene)
|
BRAF V600E • EGFR mutation • BRAF V600
|
Mekinist (trametinib) • Tagrisso (osimertinib) • Tafinlar (dabrafenib)
9ms
Open access article 👉🏼@ASCO educational handbook 2023 - free for all to read👉🏼Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors @JCO_ASCO @ASCOPost @OncoAlert @mgoudaMD https://t.co/qoDkRndgrG (@VivekSubbiah)
9 months ago
Clinical • Pan tumor
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
9ms
🚨 Featured in Best of #JCO #ASCO23 edition: Combination Dabrafenib and Trametinib vs Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant #Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134 Listen to the podcast: https://t.co/NzCxcbjBSy @jmkirkwood #melsm (@JCO_ASCO)
9 months ago
Clinical • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Opdivo (nivolumab) • Mekinist (trametinib) • Yervoy (ipilimumab) • Tafinlar (dabrafenib)
10ms
Ph II Encorafenib+Binimetinib in BRAFV600+ nsclc: - ORR 75% 1L (n=59); 46% 2L+(n=39); mDOR NE & 16.7m - TRAEs nausea 50%, diarrhea 43%, fatigue 32% Comparable outcomes to dabrafenib/trametinib with a diff AE profile @JCO_ASCO @OncoAlert https://t.co/XOD2BnywtI (@DrJNaidoo)
10 months ago
BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib) • Mektovi (binimetinib) • Braftovi (encorafenib)
10ms
Allison Betof Warner, MD, PhD, and Zeynep Eroglu, MD, on Metastatic Melanoma: New Data on Dabrafenib, Trametinib, and Navitoclax https://t.co/NRyC5s2BmM #melsm #melanoma #skincancer #oncology #ASCO23 @DrBetofMDPhD @StanfordCancer @MoffittNews (@ASCOPost)
10 months ago
Metastases
|
Mekinist (trametinib) • Tafinlar (dabrafenib) • navitoclax (ABT 263)
10ms
💥 In the context of @ASCO Plenary on brain tumor #ASCO23 👉🏼sharing a major milestone in the #precisionmedicine for BRAF + glioblastoma & the first ever positive targeted therapy for brain tumors. 👉Dabrafenib + trametinib in BRAFV600E-mutant low-grade & high-grade glioma… https://t.co/ZPV7m2CX9Y (@VivekSubbiah)
10 months ago
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
10ms
Thrilled to share our article in the ASCO educational handbook @ASCOPost @ASCO #ASCO23! Don't miss the session today 📚 "Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors" -->This practical guide… https://t.co/gX38X48QK5 (@VivekSubbiah)
10 months ago
Clinical • Pan tumor
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
10ms
🌟 Feast your eyes on these beautiful figures we created for @VivekSubbiah for the #ASCO23 educational handbook!—FREE access! 📚 "Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult &Pediatric Solid Tumors"🎯🧬 #DrawImpacts (@DrawImpacts)
10 months ago
Clinical • Pan tumor
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
10ms
🚨Just days before @ASCO 👉🏼 #ASCO23 educational handbook - free open access article is out 👉🏼Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors 🎯🧬 summarizing the latest in BRAF #PrecisionMedicine… https://t.co/70SUhtdj53 (@VivekSubbiah)
10 months ago
Clinical • Pan tumor
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
11ms
🎉 Hot off the press: Our figures now officially published in @ASCOPost educational handbook! Check out @VivekSubbiah & #MohamedGouda's article"Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E-Positive Adult and Pediatric Solid Tumors"🩺💥 (@DrawImpacts)
11 months ago
Clinical • Pan tumor
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
11ms
Excited to announce the publication of our article in the ASCO educational handbook @ASCOPost @ASCO #ASCO23! 📚 📢 "Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors" 🩺💥 This practical guide builds… https://t.co/HTPHCkQvOt (@VivekSubbiah)
11 months ago
Clinical • Pan tumor
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
11ms
NICE approve 1L Dabrafenib & Trametinib for BRAF V600E NSCLC (@tnewsomdavis)
11 months ago
NICE
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
12ms
This study in @BloodJournal showed activity in BRAF + Hairy cell leukemia 6/10👉 Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia @OncoAlert @weoncologists cc @AaronGoodman33 @Dr_R_Kurzrock @doctorpemm… https://t.co/7iLu5vEswR (@VivekSubbiah)
12 months ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
12ms
First win for #precisionmedicine in rare cancer patients from the ROAR trial 3/10👉 Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer @JCO_ASCO @ASCO lead to FDA approval in this deadly cancer #AACR23… https://t.co/lP5WSL0nDc (@VivekSubbiah)
12 months ago
Clinical • FDA event • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
12ms
🎯🧬This study showed activity in brain tumors including BRAF V600 glioblastoma ! 5/10 Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial @aacr #aacr23 @OncoAlert… https://t.co/0WPnUYBJdv (@VivekSubbiah)
12 months ago
Clinical • Pan tumor
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
12ms
Dr. @IbiayiMD at #TexasLung23 with a masterful talk on #BRAF in NSCLC noting the approved approach for NSCLC (dabrafenib + trametinib, vertical blockade) is approved for the V600E mutation but options for other relevant mutations in development. @TLCconference (@StephenVLiu)
12 months ago
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
1year
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia https://t.co/QswEGQHTDu (@VivekSubbiah)
1 year ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
1year
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia https://t.co/QswEGQHTDu (@VivekSubbiah)
1 year ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
1year
⚡️Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia @BloodJournal @OncoAlert https://t.co/QswEGQHTDu (@VivekSubbiah)
1 year ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
1year
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia @BloodJournal https://t.co/QswEGQHTDu (@VivekSubbiah)
1 year ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
1year
🚨 Thrilled to share BRAF+ MEK combo data - as a rituximab free option for patients with Hairy cell #leukemia published in @BloodJournal @ASH_hematology with an editorial commentary 👉Dabrafenib plus trametinib in patients with relapsed/refractory BRAF https://t.co/QswEGQHTDu… https://t.co/KRBYwktpmd (@VivekSubbiah)
1 year ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
Mekinist (trametinib) • Tafinlar (dabrafenib) • Rituxan (rituximab)
1year
FDA Approves Dabrafenib with Trametinib for Pediatric Patients with Low-Grade Glioma (LGG), a BRAF V600E Mutation https://t.co/S5L4uT3b87 @dipeshuprety4 (@BTFCancerNews)
1 year ago
Clinical • FDA event
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
1year
🚨 It’s Friday & another FDA approval for BRAF V600+ tumors👉🏼Tafinlar + Mekinist approved for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer. 🎯🧬Another milestone beyond the tissue agnostic approval https://t.co/ftW2zcrpGm… https://t.co/iNGsQYsEj0 (@VivekSubbiah)
1 year ago
Clinical • FDA event • Pan tumor
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
1year
T:👉 FDA, sistemik tedavi gerektiren BRAF V600E mutasyonuna sahip düşük dereceli gliomalı (LGG) 1 yaş ve üzeri pediyatrik hastalar için trametinib (Mekinist, Novartis) ile birlikte dabrafenibi (Tafinlar, Novartis) onayladı. FDA ayrıca her iki ilacın da https://t.co/5YbOuC0qW2… https://t.co/iIkwCYYEZS (@ilyassahinMD)
1 year ago
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
1year
🚨FDA APPROVAL for Dabrafenib and Trametinib for pediatric low grade glioma patients with BRAF V600E mutation @OncoAlert @FDAOncology @Cancer_Free_IND @PrecisionGlioma @GliomaGenomics @WorldSIOP #precisiononcology #precisioncancercare https://t.co/9DRcyvUbd3 (@saadvikdr)
1 year ago
Clinical • FDA event
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
1year
FDA Approves Dabrafenib Plus Trametinib for Pediatric Patients With BRAF V600E–Mutated Low-Grade Glioma https://t.co/saFu2LI5AW via @onclive (@DrBonillaOnc)
1 year ago
Clinical • FDA event
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
1year
Great Q- Here's a study looking at efficacy of IO in BRAF V600E+ NSCLC - 21 pts total, ORR 25%, PFS 3.7 mo 🔗https://t.co/7v7qTLhqDg 4 of 8 pts w BRAF V600E+ and PD-L1 high were tx 1L w dabrafenib + trametinib, and showed "tumor shrinkage" on 2L IO (@DAielloMD)
1 year ago
Clinical
|
PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
1year
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia https://t.co/uvTHFV1Z9q dual targeted therapy for RR HCL. 2 yrs OS up to 95%. (@TalhaBadarMD)
1 year ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
1year
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia | Blood | American Society of Hematology https://t.co/pPrHvlQhm5 (@SCTNB)
1 year ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
1year
In 2018 Jan - Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer 2/7 @JCO_ASCO @ASCO @OncoAlert @Aiims1742 https://t.co/gMX386Ndzp (@VivekSubbiah)
1 year ago
Clinical • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
1year
In 2018 May FDA approves dabrafenib plus trametinib for anaplastic thyroid cancer with BRAF V600E mutation 3/7 https://t.co/e8i1lxlh8g (@VivekSubbiah)
1 year ago
FDA event
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
1year
In 2022 we confirmed the definitive benefit - Dabrafenib + trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study 4/7 @Annals_Oncology @myESMO @OncoAlert https://t.co/HqtvJXyRRd (@VivekSubbiah)
1 year ago
Clinical • Pan tumor
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
1year
June 22 - 2022- FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation 6/7 https://t.co/gADXpkLDuh (@VivekSubbiah)
1 year ago
FDA event • Combination therapy • Metastases
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
1year
#TumorBoardTuesday #GI23 The last trial that I was🙏for was dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600E-mut mCRC🖥️by Chen, et al ➡️This4⃣drug combo only resulted in a mPFS of 7.5 mos, and ORR of 30% - which is very similar to encorafenib + cetux alone😔 (@MPishvaian)
1 year ago
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Erbitux (cetuximab) • Mekinist (trametinib) • Tafinlar (dabrafenib) • Braftovi (encorafenib) • irinotecan
1year
Confirming the DEFINITIVE BENEFIT of Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer. First ever therapy for anaplastic thyroid cancer @Annals_Oncology @myESMO @OncoAlert https://t.co/B2cl6E0XFP (@VivekSubbiah)
1 year ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
1year
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia @ASH_hematology https://t.co/Xa44VAPjR7 (@VivekSubbiah)
1 year ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
over1year
Dr. Subbiah on the FDA Approval of Dabrafenib/Trametinib in BRAF V600E–Mutated Solid Tumors https://t.co/TITmVinZSh via @onclive (@VivekSubbiah)
over 1 year ago
FDA event
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
over1year
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia @ASH_hematology @BloodJournal https://t.co/Xa44VAOM1z (@VivekSubbiah)
over 1 year ago
Clinical
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
over1year
⏰ Timing is everything! The DREAMseq Trial reveals combination nivolumab ➕ ipilimumab (#immunotherapy) followed by dabrafenib ➕ trametinib provides improved outcomes for pts w/ advanced BRAF-mutant #melanoma 👉 https://t.co/rHsUXvaxK8 #JCO #ImmunoOnc #melsm @jmkirkwood (@JCO_ASCO)
over 1 year ago
Clinical • IO biomarker
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Opdivo (nivolumab) • Mekinist (trametinib) • Yervoy (ipilimumab) • Tafinlar (dabrafenib)
over1year
Dr. @RamSubraMD discusses #BRAF in NSCLC. Dabrafenib plus trametimib effective as initial and salvage therapy but no new approved options available at resistance just yet. #DCLung22 (@StephenVLiu)
over 1 year ago
BRAF (B-raf proto-oncogene)
|
Tafinlar (dabrafenib)
over1year
Dabrafenib Plus Trametinib Approved as First Tumor-Agnostic Therapy for BRAF V600E–Mutated Solid Tumors https://t.co/S4LR5mjdEQ via @AJMC_Journal (@VivekSubbiah)
over 1 year ago
Pan tumor
|
BRAF (B-raf proto-oncogene)
|
BRAF V600E • BRAF V600
|
Mekinist (trametinib) • Tafinlar (dabrafenib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login